Article Details

Trastuzumab Deruxtecan Granted Priority Review From FDA for HER2-Positive Metastatic ...

Retrieved on: 2022-01-17 17:01:33

Tags for this article:

Click the tags to see associated articles and topics

Trastuzumab Deruxtecan Granted Priority Review From FDA for HER2-Positive Metastatic .... View article details on hiswai:

Excerpt

... cancer that was previously treated with an anti-HER2 regimen, according to a press release from developers Daiichi Sankyo and AstraZeneca.1.

Article found on: www.cancernetwork.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up